Lorenz Trümper - Concepedia

Author

Lorenz Trümper

Also Known As

David Townend, H. Tessen, Isabelle Treilleux, Jean-Rémi Trotta, L Trumper, L Trümper, L. H. Trumper, L. Trumper, L. Trümper, L. Trümper

469

Publications

38.5K

Citations

H-Index

115

Concepts

All Affiliations

University of Göttingen Leipzig University Saarland University University of Lübeck Charité - Universitätsmedizin Berlin

About

Lorenz Trümper is an author at University of Göttingen specializing in medicine, immunology, and pathology.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	36	78	10K
2	Health Sciences	12	14	624
3	Natural Sciences	2	2	40
4	Blood Transplantation	2	2	48
5	Engineering	1	1	37

Lorenz Trümper

185

Publications

26.6K

Citations

H-Index

Page 1

	Year	Citations
Pan-cancer analysis of whole genomes Lauri A. Aaltonen, Federico Abascal, Adam Abeshouse, Nature	2020	3.1K
CHOP-like chemotherapy plus rituximab versus CHOP-like chemotherapy alone in young patients with good-prognosis diffuse large-B-cell lymphoma: a randomised controlled trial by the MabThera International Trial (MInT) Group Michael Pfreundschuh, Lorenz Trümper, Anders Österborg, The Lancet Oncology Hematological MalignancyLymphoid NeoplasiaMabthera International TrialMedicinePathology	2006	2.1K
Molecular subtypes of diffuse large B cell lymphoma are associated with distinct pathogenic mechanisms and outcomes Bjoern Chapuy, Chip Stewart, Andrew Dunford, Nature Medicine Hematological MalignancyLymphoid NeoplasiaMolecular SubtypesImmunologyPathology	2018	1.9K
Six versus eight cycles of bi-weekly CHOP-14 with or without rituximab in elderly patients with aggressive CD20+ B-cell lymphomas: a randomised controlled trial (RICOVER-60) Michael Pfreundschuh, Jöerg Schubert, Marita Ziepert, The Lancet Oncology Hematological MalignancyLymphoid NeoplasiaElderly PatientsMedicineBi-weekly Chop-14	2008	1.1K
A Biologic Definition of Burkitt's Lymphoma from Transcriptional and Genomic Profiling Michael Hummel, Stefan Bentink, Hilmar Berger, New England Journal of Medicine	2006	1K
Reduced Treatment Intensity in Patients with Early-Stage Hodgkin's Lymphoma Andreas Engert, Annette Plütschow, Hans Theodor Eich, New England Journal of Medicine	2010	907
CHOP-like chemotherapy with or without rituximab in young patients with good-prognosis diffuse large-B-cell lymphoma: 6-year results of an open-label randomised study of the MabThera International Trial (MInT) Group Michael Pfreundschuh, Evelyn Kuhnt, Lorenz Trümper, The Lancet Oncology Hematological MalignancyLymphoid Neoplasia6-Year ResultsMabthera International TrialMedicine	2011	796
New insights into the prognostic impact of the karyotype in MDS and correlation with subtypes: evidence from a core dataset of 2124 patients Detlef Haase, Ulrich Germing, Julie Schanz, Blood	2007	783
Brentuximab vedotin with chemotherapy for CD30-positive peripheral T-cell lymphoma (ECHELON-2): a global, double-blind, randomised, phase 3 trial Steven M. Horwitz, Owen A. O’Connor, Barbara Pro, The Lancet	2018	707
Treatment and prognosis of mature T-cell and NK-cell lymphoma: an analysis of patients with T-cell lymphoma treated in studies of the German High-Grade Non-Hodgkin Lymphoma Study Group Norbert Schmitz, Lorenz Trümper, Marita Ziepert, Blood	2010	588

Page 1